TheraRadar
Clinical-Stage Companies / Inmunotek S.L.

Inmunotek S.L.

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 4/2/2025

12
Total Trials
10
Phase 3
4
Phase 2
4
Recruiting
182
Score

Pipeline by Phase

Phase 3
10
Phase 2
4
Phase 1

Therapeutic Focus

Rhinoconjunctivitis Rhinitis, Allergic Asthma, Allergic Rhinitis Allergic Rhinoconjunctivitis

Clinical Trials (12)

NCT07348302 Phase 3 RECRUITING

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Started: 4/2/2025

NCT04435990 Phase 3 RECRUITING

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Started: 10/6/2020

NCT04898283 Phase 3 RECRUITING

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Started: 5/31/2021

NCT04891237 Phase 3 RECRUITING

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Started: 6/14/2021

NCT04874714 Phase 3 TERMINATED

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

Started: 4/30/2021

NCT01734811 Phase 3 COMPLETED

Efficacy and Safety Evaluation in Recurrent Wheezing Attacks

Started: 10/1/2012

NCT02543827 Phase 3 COMPLETED

Evaluation of the Efficacy and Safety of MV140

Started: 11/1/2015

NCT04452643 Phase 3 WITHDRAWN

Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel

Started: 10/1/2020

NCT01842360 Phase 2 COMPLETED

Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)

Started: 5/6/2013

NCT05641272 Phase 2 NOT YET RECRUITING

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

Started: 11/1/2023

NCT02527187 Phase 2 COMPLETED

Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa

Started: 9/1/2015

NCT02654223 Phase 2 COMPLETED

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

Started: 12/30/2015

Drug Candidates

Allergen Immunotherapy Extract Placebo MV130 10,000 MM09 30,000 MM09 Placebo subcutaneous 10,000 MG01 +10,000 T521 30,000 MG01 +10,000 T521 10,000 MG01 + 10,000 T517 30,000 MG01 + 10,000 T517
Activity Status: Slowing
Last Trial Started: 4/2/2025
Last Trial Ended: 10/9/2023
Trials (12 months): 0
Completed Trials: 5
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.